G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes

Current Opinion in Investigational Drugs

Volumn 5, Issue 10, 2004, Pages 1051-1062

  Bjenning, Christina ^a   Al Shamma, Hussien ^a   Thomsen, William ^a   Leonard, Jim ^a   Behan, Dominic ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

Diabetes; Feeding; GPCR; Insulin; Obesity; Orphan

Indexed keywords

ANTIDIABETIC AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND;

ANIMAL; DRUG EFFECT; ENERGY METABOLISM; FOOD INTAKE; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

ANIMALS; APPETITE REGULATION; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; OBESITY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 16644392585     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. J Am Med Assoc (2003) 289(1):76-79.
2. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES: Relationship to insulin resistance on the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes (2004) 53(5):1195-2000.
3. Klabunde T, Hessler G: Drug design strategies for targeting G-protein-coupled receptors. Chembiochem (2002) 3(10):928-944.
4. Drews J: Drug discovery: A historical perspective. Science (1999) 287(5460):1960-1964.
5. Scussa F: Worlds best selling drugs. Med Adv News (2002) 21(5):1-46.
6. Wise A, Jupe SC, Rees S: The identification of ligands at orphan G-protein coupled receptors. Annu Rev Pharmacol Toxicol (2004) 44:43-66.
7. Brady AE, Limbird LE: G-protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cell Signal (2002) 14(4):297-309.
8. Bockaert J, Marin P, Dumuis A, Fagni L: The magic tail of G-coupled receptors: An anchorage for functional protein networks. FEBS Lett (2003) 546(1):65-72.
9. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB: The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analyses, paralogon, and fingerprints. Mol Pharmacol (2003) 63(6):1256-1272.
10. Karnik SS, Gogonea C, Patil S, Saad Y, Takezako T: Activation of G-protein-coupled receptors: A common molecular mechanism. Trends Endocrinol Metabol (2003) 14(9):431-437.
11. Bissantz C: Conformational changes of G-protein-coupled receptors during their activation by agonist binding. J Recept Signal Tranduction Res (2003) 23(2-3):123-153.
12. Tan CM, Brady AE, Nickols HH, Wang Q, Limbird LE: Membrane trafficking of G-protein-coupled receptors. Annu Rev Pharmacol Toxicol (2004) 44:559-609.
13. Lefkowitz RJ: G-protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem (1998) 273(30):18677-18680.
14. 2-adrenergic receptor-Src protein kinase complexes. Science (1999) 283(5402):655-661.
15. Marinissen MJ, Gutkind JS: G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol Sci (2001) 22(7):368-376.
16. Costa T, Herz A: Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA (1989) 86(19):7321-7325.
17. Kenakin T: Inverse, protean, and ligand-selective agonism: Matters of receptor conformation. FASEB J (2001) 15(3):598-611.
18. Behan DP, Chalmers DT: The use of constitutively active receptors for drug discovery at the G-protein-coupled receptor gene pool. Curr Opin Drug Discovery Dev (2001) 4(5):548-560.
19. Seifert R, Wenzel-Seifert K: Constitutive activity of G-protein-coupled receptors: Cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol (2002) 366(5):381-416.
20. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E: Lessons from constitutively active mutants of G-protein-coupled receptors. Trends Endocrinol Metab (2002) 13(8):336-343.
21. Milligan G: Constitutive activity and inverse agonists of G-protein-coupled receptors: A current perspective. Mol Pharmacol (2003) 64(6):1271-1276.
22. Kenakin T: Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Mol Pharmacol (2004) 65(1):2-11.
23. Chalmers DT, Behan DP: The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov (2002) 1(8):599-608.
24. Menzaghi F, Behan DP, Chalmers DT: Constitutively activated G-protein-coupled receptors: A novel approach to CNS drug discovery. Curr Drug Targets (2002) 1(1):105-121.
25. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ, Kenakin T: Use of constitutive G-protein-coupled receptor activity for drug discovery. Mol Pharmacol (2000) 57(1):125-134.
26. Bernard C (Ed): An Introduction to the Study of Experimental Medicine. Henry Schuman Inc, Paris, France (1949).
27. Tache Y, Garrick T, Raybould H: Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology (1990) 98(2):517-528.
28. Meier U, Gressner AM: Endocrine regulation of energy metabolism: Review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem (2004) 50(9):1511-1525.
29. Peeters TL: Central and peripheral mechanisms by which ghrelin regulates gut motility. J Physiol Pharmacol (2003) 54(Suppl 4):95-103.
30. Anand BK, Brobeck JR: Localization of feeding center in the hypothalamus of the rat. Proc Soc Exp Biol Med (1951) 77(2):323-324.
31. Ellis C: Twenty questions. The state of GPCR research in 2004. Nat Rev Drug Discov (2004) 3(7):577-626.
32. 5 receptor antagonists as anti-obesity drugs. Curr Opin Investig Drugs (2003) 4(10):1198-1204.
33. Jensen RT: Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol (2002) 91(6):333-350.
34. Martin WJ, McGowan E, Cashen DE, Gantert LT, Drisko JE, Hom GJ, Nargund R, Sebhat I, Howard AD, Van der Ploeg LH, MacIntyre DE: Activation of melanocortin MC4 receptors increases erectile activity in rats ex copula. Eur J Pharmacol (2002) 454(1):71-79.
35. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes (2002) 51(2):424-429.
36. Matthews S, Schmitz MO, Langendorf KW, Jakobsen G: A long-acting GLP-1 derivative, NN2211: Its use in the treatment of type 2 diabetes. European Association for the Study of Diabetes, Budapest, Hungary (2002):Poster 678.
37. Hansen BC, Bjenning C, Knudsen LB: Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivative, NN2211. European Association for the Study of Diabetes, Glasgow, Scotland, UK (2001):Poster 751.
38. Bjenning C, Romer J, Knudsen LB: NN2211, a Novo Nordisk GLP-1 derivate, suppresses appetite in wild type but not in GLP-1r -/-mice. North American Association for the Study of Obesity, Quebec City, Canada (2001):Poster 751.
39. Park A, Sileno A, Brandt G, Quary S, Bloom SR: Nasal peptide PYY3-36: Phase I dose ranging and safety study in healthy subjects. Int J Obesity (2004) 28(Suppl 1):S222.
40. Pissios P, Maratos-Flier E: Melanin-concentrating hormone: From fish skin to skinny mammals. Trends Endocrinol Metab (2003) 14(5):243-248.
41. Shearman LP, Camacho RE, Sloan Stribling D, Zhou D, Bednarek MA, Hreniuk DL, Feighner SD, Tan CP, Howard AD, Van der Ploeg LH, MacIntyre DE et al: Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur J Pharmacol (2003) 475(1-3):37-47.
42. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP et al: Antidepressant, anxiolytic and anorectic effects of melanin-concentrating hormone-1 receptor antagonist. Nat Med (2002) 8(8):825-830.
43. Stanley BG: Neuropeptide Y in multiple hypothalamic sites controls eating behavior, endocrine, and autonomic systems for body energy balance. In: The Biology of Neuropeptide Y and Related Peptides. Colmers WF, Wahlestedt C (Eds), Humana Press, Totowa, NJ, USA (1993):457-510.
44. Chamorro S, Della-Zuana O, Fauchere JL, Feletou M, Galizzi JP, Levens N: Appetite suppression based on selective inhibition of NPY receptors. Int J Obesity Relat Metab Disord (2002) 26(3):281-298.
45. Akabayashi A, Wahlestedt C, Alexander JT, Leibowitz SF: Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Brain Res Mol Brain Res (1994) 21(1-2):55-61.
46. 5 receptor. Int J Obesity Relat Metab Disord (2004) 28(4):628-639.
47. Segal-Lieberman G, Trombly DJ, Juthani V, Wang X, Maratos-Flier E: NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. Am J Physiol Endocrinol Metab (2003) 284(6):E1131-E1139.
48. 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obesity Relat Metab Disord (2004) 28(4):640-648.
49. Croxford JL: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs (2003) 17(3):179-202.
50. Peck P: Two-for-one pill treats smoking, obesity. United Press International (2004):March 9.
51. Glass MJ, Colago EE, Pickel VM: α-2A-adrenergic receptors are present on neurons in the central nucleus of the amygdala that project to the dorsal vagal complex in the rat. Synapse (2002) 46(4):258-268.
52. Savontaus E, Rouru J, Malminiemi K, Luukkaa V, Pesonen U, Koulu M Huupponen R: Effects of chronic celiprolol treatment on brown fat, feeding and drinking in fa/fa Zucker rats. Pharmacol Biochem Behav (2000) 65(4):719-724.
53. Susulic VS, LaVallette L, Duzic E, Chen L, Shuey D, Karathanasis SK, Steiner KE: Expression of the human P3-adrenergic receptor gene in SK-N-MC cells is under the control of a distal enhancer. Endocrinology (2001) 142 (5):1935-1949.
54. McQuade JA, Benoit SC, Xu M, Woods SC, Seeley RJ: High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene. Behav Brain Res (2004) 151(1-2):313-319.
55. Haberny SL, Berman Y, Meller E, Carr KD: Chronic food restriction increases D-1 dopamine receptor agonist-induced phosphorylation of extracellular signal-regulated kinase 1/2 and cyclic AMP response element-binding protein in caudate-putamen and nucleus accumbens. Neuroscience (2004) 125(1):289-298.
56. Sakata T, Yoshimatsu H, Kurokawa M: Hypothalamic neuronal histamine: Implications of its homeostatic control of energy metabolism. Nutrition (1997) 13(5):403-411.
57. 3 receptor antagonists/inverse agonists as anti-obesity agents. Curr Opin Investig Drugs (2003) 4(10):1190-1197.
58. 3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest (2002) 110(12):1791-1799.
59. 3-receptor antagonist. J Pharmacol Exp Ther (1988) 287(2):658-666.
60. Bjenning C, Johannesson U, Juul A-G, Lange KZ, Rimvall K: Peripherally administered ciproxifan elevates hypothalamic histamine levels and potently reduces food intake in the Sprague Dawley rat. Sendai Histamine Symposium, Sendai, Japan (2002):39-40.
61. 3 antagonist potently reduces snacking behavior in the obese Zucker rat. Sendai Histamine Symposium, Sendai, Japan (2002):40.
62. 3 receptor antagonist. Eur J Pharmacol (2004) 487(1-3):183-197.
63. 3 antagonists in models of obesity. Inflamm Res (2004) 53(Suppl 1):S47-48.
64. Brauer LH, Johanson CE, Schuster CR, Rothman RB, deWt H: Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volounteers. Neuropsychopharmacology (1996) 14(4):233-241.
65. Guy-Grand B: Clinical studies with D-fenfluramine. Am J Clin Nutr (1992) 55(Suppl 1):173S-176S.
66. Turner P: Dexfenfluramine. Its place in weight control. Drugs (1990) 39(Suppl 3):53-62.
67. 2c receptors. Neuropharmacology (2001) 41(2):200-209.
68. 2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol (2002) 161(6):2209-2218.
69. US Food and Drug Administration Center for Drug Evaluation and Research (CDER): FDA announces withdrawal of fenfluramine and dexfenfluramine. FDA (1997):September 15.
70. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102(23):2836-2841.
71. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol (2000) 57(1):75-81.
72. Michelakis ED, Weir EK: Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci (2001) 321(4):292-299.
73. 2B receptors in mice leads to abnormal cardiac structure and function. Circulation (2001) 103(24):2973-2979.
74. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight management after weight loss: A randomized trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet (2000) 356(9248):2119-2125.
75. 2C receptor mutant mice. Psychopharmacology (1999) 143(3):309-314.
76. Walsh AF, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ: m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (1994) 116(1):120-122.
77. Murphy DL, Aulakh C, Mazzola-Pomietto P, Briggs NC: Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: A preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Behav Brain Res (1996) 73(1-2):209-214.
78. Bayliss WM, Starling EH: The mechanism of pancreatic secretion. J Physiol (1902) 22:325-330.
79. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA et al: Expression cloning and signalling properties of the rat glucagon receptor. Science (1993) 259(5101):1614-1616.
80. Gerich JE: Control of glycaemia. Baillieres Clin Endocrinol Metab (1993) 7(3):551-586.
81. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB et al: Lower blood glucose, hyperglucagonemia and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA (2003) 100(3):1438-1443.
82. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D: Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science (1982) 215(4536):1115-1116.
83. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ: Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia (1994) 37(10):985-993.
84. Link JT: Pharmacological regulation of hepatic glucose production. Curr Opin Investig Drugs (2003) 4(4):421-429.
85. Djuric SW, Grihalde N, Lin CW: Glucagon receptor antagonists for the treatment of type II diabetes: Current prospects. Curr Opin Investig Drugs (2002) 3(11):1617-1623.
86. Petersen KF, Sullivan JT: Effects of a novel glucagon receptor antagonist (BAY 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia (2001) 44(11):2018-2024.
87. Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature (2001) 414(6865):821-827.
88. 2B adenosine receptors. Curr Top Med Chem (2003) 3(4):427-443.
89. 2B adenosine receptor. Bioorg Med Chem (2001) 9(10):2709-2726.
90. 2B receptor. J Med Chem (2001) 44(2):170-179.
91. Mazerbourg S, Bouley DM, Sudo S, Klein C, Zhang JV, Kawamura K, Goodrich LV, Rayburn H, Tessier-Lavigne M, Hsueh AJ: LGR4 receptor null mice exhibit intrauterine growth retardation associated with embryonic and perinatal lethality. Mol Endocrinol (2004) 18(9):2241-2254.
92. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M, Hirohashi S: Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with β-catenin mutations. Hepatology (2003) 37(3):528-533.
93. sα knockout mice. J Biol Chem (2001) 276(23):19994-19998.
94. Green A, Carroll RM, Dobias SB: Desensitization of P-adrenergic receptors in adipocytes causes increased insulin sensitivity of glucose transport. Am J Physiol (1996) 271(2 Pt 1):E271-E276.
95. iα2 in vivo ameliorates streptozotocin-induced diabetes. J Biol Chem (1998) 273(37):23649-23651.
96. αi2 enhances in vivo activation of and insulin signaling to GLUT4. J Biol Chem (2001) 276(37):34651-34658.
97. Green A, Walters DJ, Belt SE: Insulin resistance in adipocytes after downregulation of Gi subtypes. Am J Physiol (1997) 273(2 Pt 1):E254-E261.
98. iα2. Nature (1996) 379(6568):840-844.
99. αi2 enhances insulin signaling via suppression of protein-tyrosine phosphatase 1B. J Biol Chem (2001) 276(43):39705-39712.
100. Hazeki O, Okada T, Kurosu H, Takasuga S, Suzuki T, Katada T: Activation of PI 3-kinase by G protein βγ subunits. Life Sci (1998) 62(17-18):1555-1559.
101. A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats. Auton Neurosci (2000) 83(3):127-133.
102. Derave W, Hespel P: Role of adenosine in regulating glucose uptake during contractions and hypoxia in rat skeletal muscle. J Physiol (1999) 515(1):255-263.
103. Hespel P, Richter EA: Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Adv Exp Med Biol (1998) 441:97-106.
104. αq/11 protein and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem (1999) 274(47):33691-33695.
105. α11 signaling to GLUT4 glucose transporters. J Biol Chem (2001) 276(51):47751-47754.
106. Lawrence JT, Birnbaum MJ: ADP-ribosylation factor 6 delineates separate pathways used by endothelin 1 and insulin for stimulating glucose uptake in 3T3-L1 adipocytes. Mol Cell Biol (2001) 21(15):5276-5285.
107. αq/11 protein plays a key role in insulin-induced glucose transport in 3T3-L1 adipocytes. Mol Cell Biol (1999) 19(10):6765-6774.
108. Ishibashi KI, Imamura T, Sharma PM, Huang J, Ugi S, Olefsky JM: Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J Clin Invest (2001) 107(9):1193-1202.
109. q-coupled receptors. Biochem Biophys Res Commun (2000) 276(1):16-22.
110. Hajduch E, Rencurel F, Balendran A, Batty IH, Downes CP, Hundal HS: Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem (1999) 274(19):13563-13568.
111. Ahren B: Autonomic regulation of islet hormone secretion -implications for health and disease. Diabetologia (2000) 43(4):393-410.
112. Seufert J: Leptin effects on pancreatic β-cell gene expression and function. Diabetes (2004) 53(Suppl 1):S152-S158.
113. Vahl TP, D'Alessio DA: Gut peptides in the treatment of diabetes mellitus. Expert Opin Investig Drugs (2004) 13(3):177-188.
114. Habener JF: The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am (1993) 22(4):775-794.
115. Drucker DJ: Glucagon-like peptide-1 and the islet β-cell: Augmentation of cell proliferation and inhibition of apoptosis. Endocrinology (2003) 144(12):5145-5148.
116. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology (2002) 143(11):4397- 4408.
117. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology (2000) 141(12):4600-4605.
118. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M, Montminy M: cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev (2003) 17(13):1575-1580.
119. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology (2003) 144(4):1444- 1455.
120. Tseng CC, Boylan MO, Jarboe LA, Usdin TB, Wolfe MM: Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am J Physiol (1996) 270(4 Pt 1):E661-E666.
121. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept (1994) 51(1):63-74.
122. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 91(1):301-307.
123. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes (2001) 50(5):1004-1011.
124. Rask E, Olsson T, Soderberg S, Holst J, Tura A, Pacini G, Ahren B: Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism (2004) 53(5):624-631.
125. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care (2003) 26(10):2929-2940.
126. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes (2001) 50(11):2530-2539.
127. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS: Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther (2003) 307(2):490-496.
128. Giannoukakis N: CJC-1131. ConjuChem. Curr Opin Investig Drugs (2003) 4(10):1245-1249.
129. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 52(3):751-759.
130. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB: The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab (2002) 283(4):E745-E752.
131. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology (2000) 141(6):1936-1941.
132. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes (1999) 48(5):1026-1034.
133. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003) 26(8):2370-2377.
134. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 88(7):3082- 3089.
135. Egan JM, Meneilly GS, Elahi D: Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab (2003) 284(6):E1072-E1079.
136. Giannoukakis N: Exenatide. Amylin/Eli Lilly. Curr Opin Investig Drugs (2003) 4(4):459-465.
137. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes (2003) 52(7):1786-1791.
138. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR, NN2211-1310 International Study Group: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care (2004) 27(6):1335-1342.
139. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes (2004) 53(5):1187-1194.
140. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem (1993) 214(3):829-835.
141. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136(8):3585-3596.
142. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA (2000) 97(12):6874-6879.
143. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab (2004) 89(5):2078-2084.
144. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care (2002) 25(5):869-875.
145. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51(4):943-950.
146. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA: Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 52(3):741-750.
147. Fan H, Yan S, Stehling S, Marguet D, Schuppaw D, Reutter W: Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Adv Exp Med Biol (2003) 524:165-174.
148. Mentlein R, Schiemann F, Ludwig A, Brandt E: Modification of the biological activity of chemokines by dipeptidyl peptidase IV - a side effect in the use of inhibitors? Adv Exp Med Biol (2003) 524:37-47.
149. de Meester I, Lambeir AM, Proost P, Scharpe S: Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol (2003) 524:3-17.
150. Ahren B: Autonomic regulation of islet hormone secretion -implications for health and disease. Diabetologia (2000) 43(4):393-410.
151. Ahren B, Pacini G, Wynick D, Wierup N, Sundler F: Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology (2004) 145(7):3190-3196.
152. B-receptor activation inhibits exocytosis in rat pancreatic β-cells by G-protein-dependent activation of calcineurin. J Physiol (2004) 559(2):397-409.
153. Franklin IK, Wollheim CB: GABA in the endocrine pancreas: Its putative role as an islet cell paracrine-signalling molecule. J Gen Physiol (2004) 123(3):185-190.
154. 2+-sensing receptor: Expression in pancreatic islet p-cells and possible role in the regulation of insulin release. Mol Genet Metab (1999) 68(2):328-331.
155. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H et al: Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature (2003) 422(6928):173-176.
156. Briscoe CP, Littleton TR, Goetz AS, Minnick DT, Corbett DF, McKeown SC, Peat AJ, Jenkinson S: A small-molecule GPR40 agonist potentiates glucose-stimulated insulin secretion in MIN6 cells. Diabetes (2004) 56(Suppl 1):1650-P.
157. Mukhopadhyay S, Shim JY, Assi AA, Norford D, Howlett AC: CB1 cannabinoid receptor-G-protein association: A possible mechanism for differential signaling. Chem Phys Lipids (2002) 121(1-2):91- 109.
158. Freedland CS, Poston JS, Porrino LJ: Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav (2000) 67(2):265-270.
159. Smith KE, Walker MW, Artymyshyn R, Bard J, Borowsky B, Tamm JA, Yao WJ, Vaysse PJ, Branchek TA, Gerald C, Jones KA: Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem (1998) 273(36):23321-23326.
160. Holst B, Schwartz TW: Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci (2004) 25(3):113-117.
161. Wahlestedt C, Skagerberg G, Ekman R, Heilig M, Sundler F, Hakanson R: Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat. Brain Res (1987) 417(1):33-38.
162. i-coupled receptor contractile activity in the epididymis of the guinea-pig. Br J Pharmacol (1999) 127(1):85-90.
163. Stevens EB, Shah BS, Pinnock RD, Lee K: Bombesin receptors inhibit G-protein-coupled inwardly rectifying K+ channels expressed in Xenopus oocytes through a protein kinase C-dependent pathwa. Mol Pharmacol (1999) 55(6):1020-1027.
164. Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, Wada E, Wada K: Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature (1997) 390(6656):165-169.
165. Wu V, Yang M, McRoberts JA, Ren J, Seensalu R, Zeng N, Dagrag M, Birnbaumer M, Walsh JH: First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells. J Biol Chem (1997) 272(14):9037-9042.
166. Beglinger C, Degen L, Matzinger D, D'Amato M, Drewe J: Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol (2001) 280(4):R1149-R1154.
167. Rossant CJ, Pinnock RD, Hughes J, Hall MD, McNulty S: Corticotropin-releasing factor type 1 and type 2a receptors regulate phosphorylation of calcium/cyclic adenosine 3′,5′-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology (1999) 140(4):1525-1536.
168. Bradbury MJ, McBurnie MI, Denton DA, Lee KF, Vale WW: Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology (2000) 141(8):2715-2724.
169. 35S]thio)triphosphate binding in rat brain. J Neurosci Res (2000) 61(6):674-685.
170. Hussain MA, Daniel PB, Habener JF: Glucagon stimulates expression of the inducible cAMP early repressor and suppresses insulin gene expression in pancreatic β-cells. Diabetes (2000) 49(10):1681-1690.
171. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T,Weinberg D, Tota MR, Van der Ploeg LH: ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun (1997) 237(3):629-631.